Halozyme Therapeutics Inc Revenue Growth Rates (HALO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Halozyme Therapeutics Inc   (NASDAQ: HALO)
 

HALO's Revenue Growth by Quarter and Year

Halozyme Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HALO/growth
https://api.csimarket.com/api/v1/companies/HALO/fundamentals
https://api.csimarket.com/api/v1/companies/HALO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
HALO Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 492.97
2nd Quarter June 481.00
1st Quarter March 376.71
FY 1,350.68

HALOs Annual Revenue
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2025 $ 1,396.61 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2024 $ 1,015.32 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2023 $ 829.25 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2022 $ 660.12 millions
Halozyme Therapeutics Inc 's Revenue in the fiscal year 2021 $ 443.31 millions




HALO Revenue third quarter 2026 Y/Y Growth Comment
Halozyme Therapeutics Inc reported Revenue improvement of 39.16% year on year in the third quarter 2026, to $ 492.97 millions, this is lower than Halozyme Therapeutics Inc 's recent average Revenue rise of 76.08%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 20 other companies have achieved higher Revenue growth. While Halozyme Therapeutics Inc ' s Revenue rise of 39.16% ranks overall at the positon no. 491 in the third quarter 2026.


HALO Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 39.16 %
2nd Quarter June 47.67 %
1st Quarter March 42.23 %
FY   -

Financial Statements
Halozyme Therapeutics Inc 's third quarter 2026 Revenue $ 492.97 millions HALO's Income Statement
Halozyme Therapeutics Inc 's third quarter 2025 Revenue $ 354.26 millions Quarterly HALO's Income Statement


HALO Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.49 %
2nd Quarter June 27.68 %
1st Quarter March -16.61 %
FY (Year on Year)   -


Back to HALO Growth rate Comparisons >> Back to HALO Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #121
Overall #491

Revenue Y/Y Growth Statistics
High Average Low
803.86 % 76.08 % -76.75 %
(Sep 30 2013)   (Sep 30 2012)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #21
Healthcare Sector #121
Overall #491
Revenue Y/Y Growth Statistics
High Average Low
803.86 % 76.08 % -76.75 %
(Sep 30 2013)   (Sep 30 2012)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Halozyme Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
308.55 % 23.02 % -89.49 %
(Dec 31 2012)  


HALO's III. Quarter Q/Q Revenue Comment
Halozyme Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.49% quarter on quarter, to $ 492.97 millions.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Halozyme Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 394.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #86
Overall #394
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #86
Overall #394
Revenue Q/Q Growth Statistics
High Average Low
308.55 % 23.02 % -89.49 %
(Dec 31 2012)  


HALO's III. Quarter Q/Q Revenue Comment
Halozyme Therapeutics Inc achieved in the III. Quarter 2026 below company average Revenue growth of 2.49% quarter on quarter, to $ 492.97 millions.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Halozyme Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 394.


Halozyme Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,802.45
Y / Y Revenue Growth (TTM) 45.03 %
Year on Year Revenue Growth Overall Ranking # 476
Seqeuential Revenue Change (TTM) 8.34 %
Seq. Revenue Growth (TTM) Overall Ranking # 1660


Cumulative Revenue growth Comment
Halozyme Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 45.03% year on year, to $ 1,802 millions if the fiscal year would have ended in Sep 30 2026.
Halozyme Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 35.45% and higher than 41.15% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 8.34 % from $1663.74 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at35.45%.

In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 476, from total ranking in previous quarter at 609.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 116
Overall # 476

Revenue TTM Y/Y Growth Statistics
High Average Low
179.36 %
 35.45 %
-59.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 267
S&P 500 # 1660
Cumulative Revenue growth Comment
Halozyme Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 45.03% year on year, to $ 1,802 millions if the fiscal year would have ended in Sep 30 2026.
Halozyme Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 35.45% and higher than 41.15% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 8.34 % from $1663.74 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at35.45%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 8.34 % increase from $1663.74 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 115 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 476, from total ranking in previous quarter at 609.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 116
Overall # 476

Revenue TTM Y/Y Growth Statistics
High Average Low
179.36 %
35.45 %
-59.8 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 267
S&P 500 # 1660




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HALO's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Fennec Pharmaceuticals Inc 57.34%$ 57.342 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions


About Halozyme Therapeutics Inc Revenue Growth Rates (HALO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Halozyme Therapeutics Inc (CIK 1159036).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001159036-26-000145
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Halozyme Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.